Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening-Reference-Cited by-同舟云学术

Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug Screening

Published:2010-06-14 Issue:3 Volume:78 Page:456-465
ISSN:0026-895X
Container-title:Molecular Pharmacology
language:en
Short-container-title:Mol Pharmacol

Author:

Koole Cassandra,Wootten Denise,Simms John,Valant Celine,Sridhar Rohan,Woodman Owen L.,Miller Laurence J.,Summers Roger J.,Christopoulos Arthur,Sexton Patrick M.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference43 articles.

1. Application of a Kinetic Model to the Apparently Complex Behavior of Negative and Positive Allosteric Modulators of Muscarinic Acetylcholine Receptors

2. The Impact of Orthosteric Radioligand Depletion on the Quantification of Allosteric Modulator Interactions

3. Biology of Incretins: GLP-1 and GIP

4. Drugs from Emasculated Hormones: The Principle of Syntopic Antagonism

5. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabeticdb/dbmice

Cited by 197 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Isoquinoline small molecule ligands are agonists and probe-dependent allosteric modulators of the glucagon subfamily of GPCRs;Biochemical Pharmacology;2024-11

2. Ligand bias at the muscarinic acetylcholine receptor family: Opportunities and challenges;Neuropharmacology;2024-11

3. Binding sites and design strategies for small molecule GLP-1R agonists;European Journal of Medicinal Chemistry;2024-09

4. Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity;Cell;2024-09

5. Porous Silicon Microparticles Enable Sustained Release of GLP‐1R Agonist Peptides for the Treatment of Type 2 Diabetes;Advanced Therapeutics;2024-08-10